iRhythm (IRTC) vs Neogen (NEOG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Neogen (NEOG) has outperformed iRhythm (IRTC) over the past year, gaining 74.8% versus a loss of 39.6%. Over five years, IRTC leads with a +47.6% price change compared with -71.1% for NEOG. iRhythm is the larger company by market cap ($3.52 billion vs $2.59 billion), about 1.4 times the size.
On valuation, Neogen trades at a lower forward P/E (31.2x vs 83.3x for iRhythm). Neogen converts more of its revenue into profit, with a net margin of -0.9% versus -6.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRTC | NEOG |
|---|---|---|
| Share price | $106.70 | $11.85 |
| Market cap | $3.52B | $2.59B |
| 1-day change | +4.00% | +1.20% |
| YTD return | -39.87% | +69.53% |
| 1-year return | -39.57% | +74.78% |
| 5-year return | +47.60% | -71.13% |
| Forward P/E | 83.26 | 31.18 |
| EPS (TTM) | $-0.42 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $747.14M | $870.40M |
| Revenue growth (YoY) | +26.24% | -2.72% |
| Net income (latest FY) | $-44.55M | $-7.90M |
| Gross margin | 70.57% | 46.93% |
| Operating margin | -7.68% | -2.48% |
| Net margin | -5.96% | -0.91% |
| 52-week high | $212.00 | $14.26 |
| 52-week low | $100.70 | $5.37 |
| Distance from 52-week high | -49.67% | -16.90% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +63.01% | +18.14% |
| Average volume | 569.39K | 3.16M |
| Shares outstanding | 32.96M | 218.31M |
| Employees | 2,400 | 2,636 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NEOG has outperformed IRTC by 114.3 percentage points over the past year.
- Neogen is more profitable, keeping -0.9 cents of every revenue dollar as net income versus -6.0 cents for iRhythm.
- iRhythm grew revenue faster in its latest fiscal year (+26.24% vs -2.72%).
About iRhythm
IRTC stock →iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
Health Care · Medical/Dental Instruments · 2,400 employees
About Neogen
NEOG stock →Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through Food Safety and Animal Safety segments.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,636 employees
IRTC vs NEOG FAQ
Which is bigger, iRhythm or Neogen?
iRhythm (IRTC) is larger, with a market capitalization of $3.52B compared with $2.59B for Neogen (NEOG).
Which stock has performed better over the past year, IRTC or NEOG?
NEOG returned +74.78% over the past 12 months, compared with -39.57% for IRTC (price return, excluding dividends). Past performance does not predict future results.
Are iRhythm and Neogen in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for iRhythm and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Neogen.